申请人:Drysdale James Martin
公开号:US20070213328A1
公开(公告)日:2007-09-13
The use of compounds of formula (I) in therapy, particularly for the treatment of a disorder mediated by excessive or inappropriate HSP90 activity formula (I), wherein R
2
is a group of formula (IA): -(Ar
1
)
m
-(Alk
1
)
p
-(Z)
r
-(Alk
2
)
s
-Q (IA) Ar
1
, Alk
1
, Z, Alk
2
and Q being as defined in the specification; m, p, r and s are independently 0 or 1; R
3
is hydrogen, an optional substituent, or an optionally substituted (C
1
-C
6
)alkyl, aryl or heteroaryl radical; and R
4
is a carboxylic ester, carboxamide or sulfonamide group; or a salt, N-oxide, hydrate, or solvate thereof.
公式(I)化合物在治疗中的应用,特别是用于治疗由过度或不适当的HSP90活性导致的疾病,其中R2是公式(IA)的基团:-(Ar1)m-(Alk1)p-(Z)r-(Alk2)s-Q(IA)Ar1,Alk1,Z,Alk2和Q在规范中定义;m,p,r和s独立地为0或1;R3是氢,可选取代基或可选取代的(C1-C6)烷基,芳基或杂环芳基基团;R4是羧酸酯,羧酰胺或磺酰胺基团;或其盐,N-氧化物,水合物或溶剂化物。